ClinicalTrials.gg
CompletedNCT00398827Updated Jul 23, 2015

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)

A Phase 3 interventional study of Dexmedetomidine and Placebo in Anesthesia and Surgical Procedures, Elective, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-23.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the safety and efficacy of dexmedetomidine as compared to placebo when used for the sedation of subjects requiring monitored anesthesia care (MAC).

Read the detailed description

Monitored anesthesia care (MAC) is a specific anesthesia service that involves an anesthesiologist administering sedatives and analgesics to a patient while monitoring his/her vital signs. MAC is often used to supplement local and regional anesthesia for non-intubated patients undergoing non-invasive procedures and minor surgery. The goal of MAC is to relieve anxiety by inducing a minimally depressed level of consciousness while the patient is able to continuously and independently maintain a patent airway and to respond appropriately to verbal commands.

Respiratory depression is the major concern with most of the medications (midazolam, fentanyl, propofol) currently used for MAC. There is clearly an unmet need for a sedative agent that can safely be used during MAC in both healthy and high risk populations with limited adverse side effects. A medication that can attenuate anxiety and the stress response associated with surgery and procedures without causing respiratory depression is highly desirable. A medication that reduces the total amount of opioids administered during a procedure could substantially reduce complications. Such a medication could be used either alone or in combination with other agents, thereby reducing the dose and side effects of the other agents.

Dexmedetomidine (DEX) has sympatholytic, sedative, analgesic, and anxiolytic effects that attenuate the catecholamine response to perioperative stress. DEX has not been associated with respiratory depression when used alone, despite sometimes deep levels of sedation.

An estimated 325 patients (260 DEX, 65 PBO) requiring MAC sedation for an elective surgery/procedure will be randomized at approximately 25 investigative sites.

02

Conditions studied

  • Anesthesia
  • Surgical Procedures, Elective

Keywords

  • American Society of Anesthesiologists (ASA)
  • Observer's Assessment of Alertness Scale (OAA/S)
  • Aldrete Scoring System
  • Surgery or procedure using monitored care anesthesia
  • Surgery or procedure at least 30 minutes in duration
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥18 years of age)
  • (ASA) Physical Status I, II, III, or IV.
  • If female, subject is non-lactating and is either:

    1. Not of , defined as for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.
    2. Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of : oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse.
  • Subject requires monitored anesthesia care (MAC) in an operating room (OR) or procedure room with an anesthesiologist in attendance.
  • Subject requires one of the following types of elective surgeries/procedures expected to take longer than 30 minutes:

    • Orthopedic
    • Ophthalmic
    • Plastic
    • Vascular stents
    • Breast
    • AV fistulas
    • Excision of lesion.
  • Subject requires local anesthetic block.
  • Subject (or subject's legally authorized representative) has voluntarily signed and dated the document approved by the Institutional Review Board.

Exclusion criteria

Exclusion Criteria:

  • Subject has received general anesthesia within 7 days prior to study entry, has received any experimental drug within 30 days prior to study drug administration, or has been previously enrolled in this study.
  • Subject requires endotracheal intubation or laryngeal mask airway (LMA)
  • Subject has central nervous system (CNS) disease with an anticipated potential for increased intracranial pressure, an uncontrolled seizure disorder, and/or known psychiatric illness that could confound a normal response to sedative treatment.
  • Subject requires epidural or spinal anesthesia.
  • Subject has received treatment with an alpha-2 agonist or antagonist within 14 days of the scheduled surgery/procedure.
  • Subject for whom opiates, benzodiazepines, dexmedetomidine, or other alpha-2 agonists are .
  • Subject has received an intravenous (IV) opioid within one hour, or a by mouth (PO)/intramuscular (IM) opioid within 4 hours, of the start of study drug administration.
  • Subject has acute unstable angina, acute myocardial infarction documented by laboratory findings in the past 6 weeks, heart rate \<50 bpm, systolic blood pressure (SBP) \<90 mmHg, or third-degree heart block unless patient has a pacemaker.
  • Subject has known elevated serum glutamic pyruvic transaminase (/Alanine aminotransferase [ALT]) and/or serum glutamic oxaloacetic transaminase (SGOT/aspartate Aminotransferase [AST]) values of ≥2 times the within the 2 months prior to screening, and/or a history of liver failure.
  • Subject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
326 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine 0.5 mcg/kg load

    Drug: Dexmedetomidine

  • Experimental
    Dexmedetomidine 1 mcg/kg load

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of patients not requiring midazolam for rescue sedation based on achieving and/or maintaining an Observer's Assessment of Alertness/Sedation Scale (OAA/S) score ≤4

    Observer's Assessment of Alertness/Sedation Scale (OAA/S) score ≤4 (Responsiveness: Lethargic response to name spoken in normal tone; Speech: Mild slowing or thickening; Facial Expression: Mild relaxation; Eyes: Glazed or mild ptosis \[less than half the eye\])

    Time frame: Prior to start of study drug, 15 minutes after start of study drug infusion, every 5 minutes thereafter throughout the study drug infusion and every 15 minutes while the subject is in the post anesthesia care unit.

Secondary outcomes

  1. Total amount (mg) of rescue midazolam required to achieve and/or maintain sedation (OAA/S score ≤4)

    Time frame: Prior to start of study drug, 15 minutes after start of study drug infusion, every 5 minutes thereafter throughout the study drug infusion and every 15 minutes while the subject is in the post anesthesia care unit.

  2. Time from onset of study drug infusion to first dose of rescue midazolam

    Subjects who are not adequately sedated (OAA/S is \>4) may receive rescue MDZ (after attempting to achieve sedation via study drug titration).

    Time frame: After the first 15 minutes of study drug infusion

  3. Percentage of subjects who convert to alternative sedative and/or anesthetic therapy due to failure of treatment with study drug and rescue

    Time frame: Prior to start of study drug, 15 minutes after start of study drug infusion, every 5 minutes thereafter throughout the study drug infusion and every 15 minutes while the subject is in the post anesthesia care unit.

  4. Time to recovery and readiness for discharge from Post-Anesthesia Care Unit (PACU)

    Assessed by time from discontinuation of study drug to reach Aldrete score ≥9.

    Time frame: Performed every 15 minutes while the subject is in the PACU until subject is discharged.

  5. Total amount of fentanyl required for pain control

    Time frame: After the first 15 minutes of study drug infusion

  6. Anesthesiologist assessment of ease of management

    Time frame: Approximately 24 hours

  7. Anesthesiologist assessment of subject cooperation

    Time frame: Approximately 24 hours

  8. Incidence of post-operative nausea and vomiting (PONV) in the PACU and during the 24 hour follow up

    Time frame: Approximately 24 hours

  9. Overall Subject satisfaction and anxiety assessed 24 hours after study drug has been discontinued

    Time frame: 24 hours after study drug has been discontinued

07

Study locations

27 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • Loma Linda Medical Center
    Loma Linda, California 92354, United States
  • Jackson Memorial Hospital
    Miami, Florida 33136, United States
  • University of Miami
    Miami, Florida 33136, United States
  • South Miami Hospital
    Miami, Florida 33143, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287-0712, United States
  • Crossroads Research Inc.
    Owings Mills, Maryland 21117, United States
  • Chesapeake Research Group
    Pasadena, Maryland 21122, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • University of Missouri Health Care
    Columbia, Missouri 65212, United States
  • NYU School of Medicine
    New York, New York 10016, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • SUNY Upstate Medical Center
    Syracuse, New York 13210, United States
  • VAMC
    Durham, North Carolina 27705, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • The Ohio State University
    Columbus, Ohio 43210-1228, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15261, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Dallas VA Medical Center
    Dallas, Texas 75216, United States
  • Baylor Research Institute
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Scott & White Memorial Hospital
    Temple, Texas 76508, United States
  • University of Virginia
    Charlottesville, Virginia 22908-0710, United States
  • VA Medical Center
    Milwaukee, Wisconsin 53295, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2006
First posted
Nov 14, 2006
Start
Dec 2006
CompletionActual
May 2007
Last update
Jul 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00398827
Responsible party
Sponsor
First posted
Nov 14, 2006
Start date
Dec 2006
Completion
May 2007
Last update
Jul 23, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion